DPYD and dihydropyrimidine dehydrogenase deficiency: The FDA also includes pharmacogenetic information labels on the potential for severe toxicity in patients with DPD deficiency during treatment with Fluorouracil, describing the different types of adverse reaction presented by patients with homozygous or heterozygous mutations resulting from a partial or total deficiency of the DPD enzyme.